ProCE Banner Activity

HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

Slideset Download
Conference Coverage
In patients with HER2+ MBC and previous treatment with trastuzumab, pertuzumab, and T-DM1, tucatinib in combination with trastuzumab and capecitabine substantially extended survival outcomes compared with trastuzumab and capecitabine alone, including in patients with brain metastases.

Released: December 16, 2019

Expiration: December 14, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen